Machine learning can predict patients' responses to antidepressants—while disentangling drug and placebo effects

Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global ...

Science shows different psychiatric disorders might have same cause

A sweeping new study of psychiatric and genetic records has the potential to change treatment for millions of psychiatric ...

Research reveals clues as to why standard antidepressants fail for so many

A study from the University of Sydney's Brain and Mind Center reveals new clues as to why standard antidepressants fail for ...

J&J’s Caplyta doubles remission rate in MDD patients

Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...

WhiteSands Treatment Center Publishes Clinical Insights Into the Zoloft(®) Withdrawal Timeline

WhiteSands Alcohol & Drug Rehab Orlando has published a new educational resource focused on treatment considerations during ...
Mad in AmericaOpinion

Weekly Research Digest: Bad Research, Unsupported Beliefs, and Sleep Apnea

This week, Mad in America examines recent antidepressant research questioning withdrawal severity, a study of unsupported ...

First on CNN: Experimental brain therapy brings new hope for treatment-resistant depression

At Stanford, a treatment that aims magnetic pulses at the brain is showing results for people with treatment-resistant ...
Psychology Today

How Biological Beliefs Influence Medication Use

The idea that mental disorders are caused by a biological mechanism is linked with prolonged use of antidepressants and ...
EurekAlert!

Structurally distinct neurokinin-1 receptor antagonists show antidepressant-like effects in preclinical models (IMAGE)

Machine-learning–guided screening identified a structurally novel NK1 receptor antagonist that reduced depressive-like ...
Everyday Health

Exercise May Be Just As Effective at Relieving Depression As Medication and Therapy

Regular exercise can ease depression as much as talk therapy and medication, a review finds — but it's not sufficient on its ...

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...
The Barre-Montpelier Times Argus

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

DENVER, CO / / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous ...